BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Corvus Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Corvus Pharmaceuticals's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07441395-1499@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:soquelitinib: Phase 2 readout est. (NCT07441395)
DESCRIPTION:soquelitinib\, phase 2\, Atopic Dermatitis.\nStudy: Study to Ev
 aluate Soquelitinib in Participants With Moderate to Severe AD\nEstimated 
 primary completion: June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/soquelitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07441395
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561048-1499@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:soquelitinib: Phase 3 readout est. (NCT06561048)
DESCRIPTION:soquelitinib\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: So
 quelitinib vs Standard of Care in Participants With Relapsed/Refractory Pe
 ripheral T-cell Lymphoma Not Otherwise Specified\, Follicular Helper T-cel
 l Lymphomas\, or Systemic Anaplastic Large-cell Lymphoma\nEstimated primar
 y completion: November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/soquelitinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06561048
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
